Acelyrin Belatedly Drops Izokibep In Its Lead Indications

The group has stopped further development of the IL-17A inhibitor in hidradenitis suppurativa and psoriatic arthritis, and intends to pivot to a thyroid eye disease therapy.  

Acelyrin HQ
• Source: Acelyrin

More from Strategy

More from Business